SCHEMBL2353554

SCHEMBL2353554

CC(C)c1ccc2c(c1)C(O)CC(C)(C)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR3 O15455 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CTSD P07339 1/20 0.37
BACE1 P56817 1/20 0.37
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
SIRT2 Q8IXJ6 3/20 0.33
SIRT1 Q96EB6 2/20 0.33
TRPV1 Q8NER1 4/20 0.33
CYP19A1 P11511 1/20 0.33
PTGS1 P23219 2/20 0.32
PTGS2 P35354 1/20 0.32
TRPA1 O75762 1/20 0.32
CACNA1C Q13936 1/20 0.32
MAPT P10636 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2353551 1.00 TLR3 (0.41) TLR3MEN1KMT2ACTSDBACE1
SCHEMBL2352016 0.82 CTSD (0.35) MEN1KMT2ACTSDBACE1LTB4R
SCHEMBL2352025 0.82 CTSD (0.35) MEN1KMT2ACTSDBACE1LTB4R
SCHEMBL3196419 0.82 CTSD (0.35) MEN1KMT2ACTSDBACE1LTB4R
SCHEMBL13090968 0.80 KMT2A (0.46) TLR3MEN1KMT2ACNR1CNR2
SCHEMBL7608955 0.80 MAPT (0.46) TLR3MEN1KMT2ACNR1CNR2
SCHEMBL3319434 0.78 KCNE1 (0.44) TLR3MEN1KMT2ATRPV1CFTR
SCHEMBL9141913 0.78 TLR3 (0.43) TLR3MEN1KMT2ACTSDBACE1
SCHEMBL3319440 0.78 KCNE1 (0.44) TLR3MEN1KMT2ATRPV1CFTR
SCHEMBL27696921 0.75 CTSD (0.33) CTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008250-B2 1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-9,10-dimethyl-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(19),15,17-triene-8,11-dione; secretase inhibitor; neurological, vascular disorders, beta-amyloid generation/aggregation; Alzheimer's disease, Down's Syndrome, cognitive impairment, amyloid neuropathies NOVARTIS AG (CH) 2011-08-30 US disclosed
US-20080214526-A1 Macrocyclic Compounds and Compositions Useful as Bace Inhibitors NOVARTIS AG (CH) 2008-09-04 US disclosed
EP-1838680-A2 MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2007-10-03 EP disclosed
WO-2006074940-A2 MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214526-A1 Macrocyclic Compounds and Compositions Useful as Bace Inhibitors BACE1, BACE2, APP TLR3 4811/4885MEN1 116/4885KMT2A 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.